Platelet factor 4

Drug Profile

Platelet factor 4

Alternative Names: Endostatin B; Iroplact; PF4; Replistatin; RG 1001; rhPF 4; rPF4

Latest Information Update: 11 Nov 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Repligen
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders; Colorectal cancer; Glioma; Kaposi's sarcoma; Malignant melanoma; Renal cancer

Most Recent Events

  • 11 Nov 2003 Discontinued - Phase-II for Coagulation disorders in USA (IV)
  • 11 Nov 2003 Discontinued - Phase-II for Colorectal cancer in USA (unspecified route)
  • 11 Nov 2003 Discontinued - Phase-II for Glioma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top